Soleno Therapeutics (SLNO) Asset Writedowns and Impairment (2016 - 2019)
Soleno Therapeutics' (SLNO) quarterly Asset Writedowns and Impairment came in at $45000.0 in Q2 2019, down 16.67% year-on-year from $54000.0 in Q2 2018, and down 2.17% on a QoQ basis from $46000.0 in Q1 2019.
Soleno Therapeutics (SLNO) Asset Writedowns and Impairment (2016 - 2019) Analysis & Trends
Soleno Therapeutics (SLNO) has 4 years of Asset Writedowns and Impairment data on file, last reported at $45000.0 in Q2 2019.
- On a quarterly basis, Asset Writedowns and Impairment fell 16.67% year-over-year to $45000.0 in Q2 2019; TTM through Sep 2019 was $169000.0, a 39.64% decrease from a year earlier, with the FY2018 full-year figure at $275000.0, down 1.08% from the prior year.
- Asset Writedowns and Impairment for Q2 2019 stood at $45000.0, down from $46000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for SLNO reached as high as $83000.0 in Q4 2017 and fell as low as $24404.0 in Q4 2016.
- Historically, Asset Writedowns and Impairment has averaged $60764.0 across 4 years, with a median of $61000.0 in 2018.
- Across the five-year window, Asset Writedowns and Impairment soared 240.11% in 2017 and plunged 43.9% in 2019, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $24404.0 in 2016, then surged by 240.11% to $83000.0 in 2017, then decreased by 6.02% to $78000.0 in 2018, then sank by 42.31% to $45000.0 in 2019.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $45000.0 in Q2 2019, $46000.0 in Q1 2019, and $78000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 45,000.00 |
| Jun 30, 2019 | 45,000.00 |
| Mar 31, 2019 | 46,000.00 |
| Mar 31, 2019 | 46,000.00 |
| Dec 31, 2018 | 78,000.00 |
| Dec 31, 2018 | 78,000.00 |
| Sep 30, 2018 | 61,000.00 |
| Sep 30, 2018 | 61,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Mar 31, 2018 | 82,000.00 |
| Mar 31, 2018 | 82,000.00 |
| Dec 31, 2017 | 83,000.00 |
| Dec 31, 2017 | 83,000.00 |
| Sep 30, 2017 | 82,000.00 |
| Sep 30, 2017 | 82,000.00 |
| Jun 30, 2017 | 68,000.00 |
| Jun 30, 2017 | 68,000.00 |
| Mar 31, 2017 | 45,000.00 |
| Mar 31, 2017 | 45,000.00 |